Dr. Reddy's Laboratories Announces the Launch of Ziprasidone Mesylate for Injection in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124 NSE: DRREDDY NYSE: RDY along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Ziprasidone Mesylate for Injection 20 mg (base)/mL Single-dose Vials the therapeutic generic equivalent of Geodon® (ziprasidone mesylate) Injection 20 mg/mL approved by the U.S. Food and Drug Administration (USFDA).

“We’re pleased to bring the first generic of Ziprasidone Mesylate for Injection to market for patients who will benefit from access to affordable medicine. With every new product launch we believe we are making healthcare more affordable by delivering value to the pharmacy” explains Marc Kikuchi Chief Executive Officer North America Generics Dr. Reddy’s Laboratories. “This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio and drive growth within the hospital segment.”

The Geodon® brand had U.S. sales of approximately $21.8 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone mesylate for injection is not approved for the treatment of patients with Dementia-Related Psychosis.

Geodon® is a trademark of Pfizer

*IQIA Retail and Non-Retail MAT January 2020

Latest Press Release on Drug News

Happy Fruit Redefines Wellness with THCV-Infused Gummies: A Breakthrough in Cannabinoid Innovation and Metabolic Supplements

Unlocking the Power of THCV: Happy Fruit's New Gummies Suppress Appetites and Provide Metabolic Support * OCEANSIDE, Calif. , April 18, 2024 /PRNewswire/ -- Happy Fruit ...

41st International Conference on Drug Discovery and Drug delivery system

On behalf of the organizing committee its great pleasure to invite to all attendees of the "41st International Conference on Drug Discovery and Drug Delivery System" taking place on November...

London Research & Pharmaceuticals presents the Advancement of LRP-661, their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami

LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), hig...

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq...

SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2/PD-L1 Bispecific Antibody Drugs

CHICAGO , April 11, 2024 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has bee...